In its second pipeline-boosting deal in two days, Sanofi has pledged €469 million (around $490 million) upfront for rights to an anti-TL1A therapy being developed by Teva for inflammatory bowel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback